Amy Schulman

Managing Partner

Amy is a managing partner in the New York office who focuses on investing in healthcare companies and early stage biotech start ups.

She currently serves as executive chair of Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY). She represents Polaris as a director of Kallyope, Thirty Madison, SQZ Biotech, ByHeart, QurAlis, and Larkspur. Amy also serves on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology. She is a member of Singapore’s Health and Biomedical Sciences International Advisory Council and the LifeSci NYC Advisory Council.

Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. She also co-founded and manages the Polaris Innovation Fund which was formed in 2017.

Prior to joining Polaris, Amy worked at Pfizer where she held a number of roles beginning with General counsel and moving to the business side as president of Pfizer Nutrition, and president of Pfizer Consumer Healthcare.

Amy has received numerous awards including the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List, Fierce Biotech’s Top 15 Women in Biotech, and Fortune Magazine’s 50 Most Powerful Women in Business.

Amy is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.